Herbort, Carl P

Kuiper, Jonas J W

Papasavvas, Ioannis

Utrecht University Repository

Papasavvas et al. Journal of Ophthalmic Inflammation and Infection           (2023) 13:10  https://doi.org/10.1186/s12348-023-00326-5BRIEF REPORT© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.Open AccessJournal of OphthalmicInammation and InfectionSome practical issues about HLA-A29 in birdshot retinochoroiditisIoannis Papasavvas1, Jonas J. W. Kuiper2 and Carl P. Herbort Jr1* To the editorHLA-A29 birdshot retinochoroiditis (BRC) is a bilat-eral posterior uveitis which affects simultaneously, although independently, the retina and the choroid. The retinal presentation is marked by vasculitis, involv-ing both small and large vessels, papillitis and macular oedema while choroidal involvement takes the form of a primary stromal choroiditis, with active, often occult, foci occupying the middle stroma of the choroid only detected by indocyanine green angiography (ICGA) at onset. These foci give rise, after several months of evo-lution without treatment, to cicatricial areas, appearing as oval cream-coloured lesions of the posterior pole and mid periphery that do not appear any more on ICGA as they are not full-thickness scars [1] (Figs. 1 and 2). BRC It is classified as an MHC-I (major histocompatibility com-plex class I)-opathy [2, 3], with the MHC-I antigen HLA-A29 occurring in ~ 100% of cases (most commonly the HLA-A*29:02 allele) compared to 5–10% of the Western population. In addition, MHC-I pathway genes ERAP1 and ERAP2 are genetically associated with BRC [3]. The combination of these genes contributes to a higher dis-ease risk than each gene alone, indicating that ERAP1, ERAP2, and HLA-A29 work together in the pathogen-esis of BRC [3], which challenges the view that BCR also occurs in HLA-A29-negative cases.BRC is a preoccupying diagnosis when it is announced to the patient because of the genetic predisposition it bears with it. Patients are often concerned for the other members of their family. Several of our patients asked us to search for the presence of the HLA-A29 antigen in their kinship. When HLA-A29 is negative by PCR or DNA sequencing methods in the relative, there is a close to 100% chance that the diagnosis can be excluded [4]. There is quasi no such a thing as an HLA-A29 negative BRC. HLA-A29 typing remains a "sine qua non" diag-nostic criterion. In spite of recent classification criteria based on claims from case series contesting this idea, still speaking of a 90 to 95% positivity rate probably relying on outdated testing methods [5], two genetic studies of over hundred patients indicate ~ 100% positivity for HLA-A29 [3, 6] Hence, it was necessary to rectify the inappropriate diagnostic criteria of 2006 [7], asserting that HLA-A29 was an essential diagnostic criterion and not only a “sup-portive” element, among other rectifications [8]. Indeed, the 32 BRC patients seen in our centre were all HLA-A29 positive [9], as well as the patients included in a French cohort by Gelfman et  al., showing that all 262 patients with birdshot were retrospectively HLA-A29 positive [6].Confronted with a BRC patient who fears that his rela-tive may present the disease, in case of absence of HLA-A29, the answer of the clinician hence is quite simple and allows to reassure totally the family indicating that there is no chance to develop the disease. The situation is completely different when the relative is also HLA-A29 positive, a situation we encountered recently where the younger sister of a BRC patient was also HLA-A29 positive. Although HLA-A29 positivity is not sufficient to develop the disease and co-factors are needed to be present, it is not possible to assure with certainty that the disease will never develop. Indeed, familial cases of *Correspondence:Carl P. Herbort Jrcph@herbortuveitis.ch1 Inflammatory and Retinal Eye Diseases, Centre for Ophthalmic Specialised Care (COS), Rue Charles‑Monnard, 6, 1003, Lausanne, Switzerland2 Department of Ophthalmology, Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The NetherlandsPage 2 of 3Papasavvas et al. Journal of Ophthalmic Inflammation and Infection           (2023) 13:10 BRC have been described [10]. We asked ourselves how the situation should be handled practically? The patient was aware that other genes had been identified for BRC. Indeed, dysfunction at the level of ERAP1 and ERAP2 may favour BRC in HLA-A29-positive individuals [2, 3]. The absolute risk of BRC is significantly higher when all three risk gene variants are carried, but pre-emptive genetic testing for ERAP1 and ERAP2 polymorphisms does not improve BRC  prediction in HLA-A29-positive individuals to a clinically meaningful extent [2, 6].Instead, it would be far more valuable to opt for pio-neering pragmatism and  have a clinical work-up per-formed and inform the healthy person of the possible symptoms. In case of such a preventive follow-up the crucial investigation to perform is ICGA, that can reveal subclinical/preclinical involvement through detection of occult hypofluorescent dark dots (HDDs) [11] (Fig. 2).Fig. 1 Advanced case of BRC with numerous cream‑coloured BRC fundus lesionsFig. 2 HLA‑A29 BRC. ICGA is essential for early diagnosis of disease and for monitoring disease activity. A Patient complaining of floaters and “dim” vision. Because of bilateral oedematous optic discs, an angiography was performed showing numerous HDDs on ICGA in the posterior pole and midperiphery (top right). HLA‑A29 testing was positive. B BRC patient who had been treated with immunosuppressives, with numerous cream‑coloured BRC fundus lesions, who’s ICGA did not show any HDDs, indicating inactivity of disease. C cartoon inspired from Mirò, showing that cream coloured BRC lesions are choroidal scars (yellow discs), (not appearing on ICGA), while black round spheres represent active choroidal foci identified by ICGA. Fundus lesions and HDDs on ICGA should not be confusedPage 3 of 3Papasavvas et al. Journal of Ophthalmic Inflammation and Infection           (2023) 13:10  A complete uveitis work up was negative with nor-mal visual fields and a normal ICGA in the relative of our patient. Because of the fears of the younger sister of our patient, we proposed an annual follow-up visit with visual field testing, one of the sensitive functional signs to monitor in BRC, and an ICGA in case of a suspicion. Until further genetic testing is routinely available that can potentially predict risk factors, the most sensible attitude in case of suspicion in a healthy HLA-A29 positive rela-tive of a BRC patient, probably is to perform a relevant clinical examination that must include ICGA, the most sensitive modality to detect pre-clinical disease [11].AbbreviationsHLA  Human leukocyte antigenBRC  Birdshot retinochoroiditisICGA  Indocyanine green angiographyMCH‑I  Major histocompatibility complex class IERAP  Endoplasmic reticulum aminopeptidasePCR  Polymerase chain reactionDNA  Deoxyribonucleic acidHDDs  Hypofluorescent dark dotsAuthors’ contributionsCPH: writing, editing, supervision; IP: writing, editing; JJWK: writing, editing. The author(s) read and approved the final manuscript.FundingWe did not receive any funding.Availability of data and materialsFor data, please refer to corresponding author.DeclarationsEthics approval and consent to participateThis brief report has been performed in accordance with the ethical standards as laid down in 1964 by the declaration of Helsinki and its later amendments. Anonymous case reports are approved by the ethics committee of our institu‑tion (ECCOS‑MTC) as long as written consent is obtained from the patients.Consent for publicationConsent was signed by all the patients.Competing interestsNo conflict of interest.Received: 6 December 2022   Accepted: 21 January 2023References 1. Papadia M, Pavésio C, Fardeau C, Neri P, Kestelyn PG, Papasavvas I, Herbort CP (2021) HLA‑A29 Birdshot Retinochoroiditis in Its 5th Decade: Selected Glimpses into the Intellectual Meanderings and Progresses in the Knowledge of a Long‑Time Misunderstood Disease. Diagnostics (Basel) 11(7):1291. https:// doi. org/ 10. 3390/ diagn ostic s1107 1291. (PMID:34359373;PMCID:PMC8305470) 2. Kuiper JJW, Setten JV, Devall M, Cretu‑Stancu M, Hiddingh S, Ophoff RA, Missotten TOAR, Velthoven MV, Den Hollander AI, Hoyng CB, James E, Reeves E, Cordero‑Coma M, Fonollosa A, Adán A, Martín J, Koeleman BPC, Boer JH, Pulit SL, Márquez A, Radstake TRDJ (2018) Functionally distinct ERAP1 and ERAP2 are a hallmark of HLA‑A29‑(Birdshot) Uveitis. Hum Mol Genet 27(24):4333–4343. https:// doi. org/ 10. 1093/ hmg/ ddy319. (PMID:30215709;PMCID:PMC6276832) 3. Kuiper JJW, Venema WJ (2020) HLA‑A29 and Birdshot Uveitis: Further Down the Rabbit Hole. Front Immunol. 11:599558. https:// doi. org/ 10. 3389/ fimmu. 2020. 599558. (PMID: 33262772; PMCID: PMC7687429) 4. Wender JD, Fu AD, Jumper JM, McDonald HR, Johnson RN, Cunning‑ham ET Jr (2008) False negative antibody‑based HLA‑A29 typing in two patients with birdshot chorioretinopathy. Br J Ophthalmol 92(8):1153–1154. https:// doi. org/ 10. 1136/ bjo. 2007. 125666. (PMID:18653613) 5. Standardization of Uveitis Nomenclature (SUN) Working Group (2021) Classification Criteria for Birdshot Chorioretinitis. Am J Ophthalmol. 228:65–71. https:// doi. org/ 10. 1016/j. ajo. 2021. 03. 059. (Epub 2021 Apr 15. PMID: 33845003; PMCID: PMC8517033) 6. Gelfman S, Monnet D, Ligocki AJ, Tabary T, Moscati A, Bai X, Freuden‑berg J, Cooper B, Kosmicki JA, Wolf S, Ferreira MAR, Overton J, Weyne J, Stahl EA, Baras A, Romano C, Cohen JHM, Coppola G, Brézin A (2021) Regeneron Genetics Center. ERAP1, ERAP2, and Two Copies of HLA‑Aw19 Alleles Increase the Risk for Birdshot Chorioretinopathy in HLA‑A29 Car‑riers. Invest Ophthalmol Vis Sci. 62(14):3. https:// doi. org/ 10. 1167/ iovs. 62. 14.3. (PMID: 34727153; PMCID: PMC8572510) 7. Levinson RD, Brezin A, Rothova A, Accorinti M, Holland GN (2006) Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am J Ophthalmol 141(1):185–187. https:// doi. org/ 10. 1016/j. ajo. 2005. 08. 025. (PMID: 16386995) 8. Herbort CP Jr, Pavésio C, LeHoang P, Bodaghi B, Fardeau C, Kestelyn P, Neri P, Papadia M (2017) Why birdshot retinochoroiditis should rather be called ‘HLA‑A29 uveitis’? Br J Ophthalmol. 101(7):851–855. https:// doi. org/ 10. 1136/ bjoph thalm ol‑ 2016‑ 309764. (Epub 2017 Mar 17. PMID: 28314830; PMCID: PMC5530806) 9. Elahi S, Lages V, Jeannin B, Herbort CP (2020) Advanced Cases of Birdshot HLA‑A29 Retinochoroiditis: Prevalence and Characteristics. Klin Monbl Augenheilkd. 237(4):431–440. https:// doi. org/ 10. 1055/a‑ 1081‑ 1683. (Epub 2020 Apr 24 PMID: 32330990) 10. Tsui E, Takhar JS, Joye A, Ahmad TR, Acharya NR, Gonzales JA (2021) High Resolution DNA Typing of Human Leukocyte Antigen A29 in Familial Bird‑shot Chorioretinopathy. Ocul Immunol Inflamm 29(2):228–231. https:// doi. org/ 10. 1080/ 09273 948. 2019. 16821 73. (Epub 2019 Nov 13 PMID: 31718387) 11. Papadia M, Herbort CP Jr (2015) New concepts in the appraisal and management of birdshot retinochoroiditis, a global perspective. Int Ophthalmol 35(2):287–301. https:// doi. org/ 10. 1007/ s10792‑ 015‑ 0046‑x. (Epub 2015 Feb 14 PMID: 25680419)Publisher’s NoteSpringer Nature remains neutral with regard to jurisdictional claims in pub‑lished maps and institutional affiliations.

Some practical issues about HLA-A29 in birdshot retinochoroiditis

https://dspace.library.uu.nl/bitstream/1874/450391/1/s12348-023-00326-5.pdf

Some practical issues about HLA-A29 in birdshot retinochoroiditis

Abstract

Similar works

Full text

Available Versions

Utrecht University Repository